Favipiravir
Viral RNA-dependent RNA polymerase inhibitor / Favipiravir is an inhibitor of Influenza viruses A, B, and C (IC50’s: A = 0.03-0.20 µg/mL H1N1, 0.01-0.30 H2N2, 0.08-0.48 H3N2, 0.14-0.15 H4N2, 0.24-1.60 H7N2, 0.20-0.82 H5N1, 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir.1,2,3 It displayed no cytotoxicity in a variety of cells. Favipiravir selectively inhibits viral RNA-dependent RNA polymerase.4 Favipiravir has also shown activity against other viruses including arena, phlebo, hanta, flavi, entero, alpha, respiratory syncytial, and noroviruses.5 In clinical trials for treatment of SARS-CoV-2.6,7
Biochemicals & reagents
259793-96-9
T-705
1) Furuta et al. (2002), In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705; Antimicrob. Agents Chemother., 46 977 2) Takahashi et al. (2003), In Vitro and In Vivo Activities of T-705 and Oseltamivir Against Influenza Virus; Antivir. Chem. Chemother., 14 235 3) Sleeman et al. (2010), In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses; Antimicrob. Agents Chemother., 54 2517 4) Furuta et al. (2005), Mechanism of action of T-705 against influenza virus; Antimicrob. Agents Chemother., 49 981 5) Furuta et al. (2013), Favipiravir (T-705), a Novel Viral RNA Polymerase Inhibitor; Antiviral Res., 100 446 6) Dong et al. (2020), Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19); Drug Discov.Ther., 14 58 7) Tu et al. (2020), A Review of SARS-CoV-2 and the Ongoing Clinical Trials; Int. J. Mol. Sci., 21 E2657
-20°C
DISEASE AREA: Infectious disease